NATCO Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NSEI:NATCOPHARM Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
19 Dec 24	Sell₹7,336,084	Sadasiva Nannapaneni	Individual	5,000	₹1,467.22
29 Nov 24	Sell₹1,352,855	Rahul Tummala	Individual	1,000	₹1,352.85
27 Nov 24	Sell₹1,223,319	Rahul Tummala	Individual	900	₹1,359.24
11 Sep 24	Sell₹2,426,355	Amit Sogani	Individual	1,500	₹1,617.57
05 Sep 24	Sell₹2,039,178	Sunil Kotaru	Individual	1,310	₹1,556.62
04 Sep 24	Sell₹3,066,041	G. Ramana	Individual	2,000	₹1,533.02
30 Aug 24	Sell₹30,279,974	Mente Rao	Individual	20,000	₹1,514.00
22 Aug 24	Sell₹936,053	Dhruva Nannapaneni	Individual	600	₹1,560.09
21 Aug 24	Sell₹14,561,257	N. Srilakshmi	Individual	10,000	₹1,456.13
28 Jun 24	Sell₹585,315	M. Reddy	Individual	500	₹1,170.63
26 Jun 24	Sell₹2,893,020	Venkata Kurra	Individual	2,415	₹1,197.94
25 Jun 24	Sell₹482,918	Tummala Rao	Individual	400	₹1,207.29
25 Jun 24	Sell₹1,010,016	Sunil Kotaru	Individual	840	₹1,202.40
24 Jun 24	Sell₹6,000,000	Potluri Prasad	Individual	5,000	₹1,200.00
24 Jun 24	Sell₹20,400	Sandeep Kurra	Individual	17	₹1,200.00
20 Jun 24	Sell₹1,173,530	Praveen Myneni	Individual	999	₹1,174.70
03 Jun 24	Sell₹1,373,488	Pratima Jain	Individual	1,375	₹998.90

Insider Trading Volume

Insider Buying: NATCOPHARM insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of NATCOPHARM?
Owner Type	Number of Shares	Ownership Percentage
State or Government	848,021	0.473%
Institutions	31,947,685	17.8%
Private Companies	41,202,920	23%
General Public	51,543,381	28.8%
Individual Insiders	53,567,863	29.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 68.46% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
25.1%	Venkaiah Nannapaneni	44,959,115	₹62.3b	0%	no data
9.59%	Time Cap Pharma Labs Ltd.	17,175,420	₹23.8b	0%	no data
8.81%	Natsoft Information Systems Pvt. Ltd.	15,784,900	₹21.9b	0%	no data
3.04%	Life Insurance Corporation of India, Asset Management Arm	5,438,591	₹7.5b	-17.7%	0.05%
2.28%	Neelima Nannapanenni Trust	4,082,750	₹5.7b	0%	no data
2.19%	Mirae Asset Global Investments Co., Ltd.	3,930,272	₹5.4b	0%	0.05%
1.98%	Durga Nannapaneni	3,539,100	₹4.9b	0%	no data
1.93%	The Vanguard Group, Inc.	3,463,151	₹4.8b	0.21%	no data
1.92%	Belgrave Investment Fund	3,445,000	₹4.8b	0%	no data
1.73%	ICICI Prudential Asset Management Company Limited	3,094,308	₹4.3b	0%	0.08%
1.55%	Nomura Holdings Inc, Securities & Investment Arm	2,778,500	₹3.9b	0%	0.17%
1.22%	Tata Asset Management Limited	2,181,685	₹3.0b	2.6%	0.29%
1.05%	quant Money Managers Ltd.	1,875,579	₹2.6b	0%	0.26%
1.01%	Akash Bhanshali	1,800,788	₹2.5b	0%	no data
0.92%	BlackRock, Inc.	1,645,520	₹2.3b	-2.75%	no data
0.87%	Dimensional Fund Advisors LP	1,557,589	₹2.2b	0.99%	no data
0.63%	Rajeev Nannapaneni	1,128,000	₹1.6b	0%	no data
0.52%	Norges Bank Investment Management	936,207	₹1.3b	0%	no data
0.47%	Investor Education and Protection Fund (IEPF)	847,921	₹1.2b	-0.79%	no data
0.33%	Durga Devi Nannapanei Family Trust	600,000	₹831.8m	0%	no data
0.32%	T. Anila	564,920	₹783.1m	-5.83%	no data
0.32%	Causeway Capital Management LLC	564,413	₹782.4m	8.23%	0.04%
0.25%	Canara Robeco Asset Management Company Limited	440,552	₹610.7m	0%	0.06%
0.23%	T. Ananda Babu	413,205	₹572.8m	0%	no data
0.21%	Vidyadhari Tummala	367,200	₹509.0m	-17%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 18:33
End of Day Share Price	2025/01/02 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NATCO Pharma Limited is covered by 26 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Prashant Nair	Ambit Capital
Sriraam Rathi	Anand Rathi Shares and Stock Brokers Limited
null null	Anand Rathi Shares and Stock Brokers Limited